Remo CRO

News

ACRP Expands Member Benefits to Support Continuing Education in Clinical Research

01.18 2018.

The Association of Clinical Research Professionals (ACRP) today announces an expanded portfolio of member benefits to support continuing education in the clinical research community. ACRP’s 13,000-plus global members now have free yearly access to nearly 80 continuing education programs designed to support professional development and improve the operational performance of clinical trial sites, sponsors, CROs, […] Details

Patient Centricity in Clinical Trials: When Searching is a Struggle

01.18 2018.

It’s no secret—it’s not easy for a patient to find a relevant clinical study. Heck, it isn’t easy for a research pharmacist like me to help a patient find a relevant trial; yet, patients and caregivers are looking. ClinicalTrials.gov serves almost 200 million page views/month, and that does not count the number of times it […] Details

Tufts Study Highlights Trial Data Woes

01.18 2018.

Rising piles of data amassed in clinical trials are contributing to longer development times and straining technical and integration capabilities for clinical data management staff, according to a recently completed analysis by the Tufts Center for the Study of Drug Development (CSDD). Despite improvements and enhancements in data management technologies supporting clinical trials, during the […] Details

AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis

01.17 2018.

NORTH CHICAGO, Ill., Jan. 8, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the… Details

Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

01.17 2018.

WALTHAM, Mass., Jan. 10, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today… Details

Executive Director’s Message: All Hands in On Patient Recruitment and Retention

01.17 2018.

Clinical Researcher—January 2018 (Volume 32, Issue 1) EXECUTIVE DIRECTOR’S MESSAGE Jim Kremidas [DOI: 10.14524/CR-18-4006] It’s no accident that our first issue of Clinical Researcher in 2018 is focused on patient engagement. Patients are the driving force behind clinical trials. Identifying the right patients, recruiting them, and retaining them for the duration of a trial are […] Details